3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Melanoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Rare Diseases
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Multiple Myeloma
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Hypertension, Portal
1
Hepatitis C
1
Fibrosis
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma, Follicular
1
Interventions
Rituximab
67
Cyclophosphamide
41
fludarabine phosphate
17
Etoposide
17
Doxorubicin
17
Vincristine
16
Prednisone
16
Filgrastim
14
Mycophenolic Acid
13
Cyclosporine
13
Lenalidomide
12
Antilymphocyte Serum
12
Gemcitabine
11
Radiotherapy
10
fludarabine
9
Peripheral Blood Stem Cell Transplantation
9
Methotrexate
9
Whole-Body Irradiation
8
Tacrolimus
8
Melphalan
8
Carboplatin
8
Bortezomib
8
venetoclax
7
Dexamethasone
7
Cord Blood Stem Cell Transplantation
7
Busulfan
7
ibritumomab tiuxetan
6
Ifosfamide
6
Flow Cytometry
6
obinutuzumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, Large B-Cell, Diffuse
×
tremelimumab
×
Clear all
NCT02205333
2017-06-28
MEDI6469
MedImmune LLC
Phase 1/2
Terminated
48 enrolled
28 charts